

P.O. Box 8738, Dayton, OH 45401-8738 | CareSource.com

Re: Summary of PDL Changes Effective April 1, 2024

Dear CareSource Member:

Your health care is our priority. That is why we are writing to tell you that on January 1, 2024, CareSource will change its Preferred Drug List (PDL). A PDL is a list of preferred drugs.

THE FOLLOWING MEDICINES WILL BE PREFERRED ON THE PDL EFFECTIVE APRIL 1. 2024.

Brand Name	Generic Name	Dose(s)	Notes
Airduo	Fluticasone/ Salmeterol	All strengths of Respiclick inhaler	
Dymista	Azelastine/ Fluticasone	137-50 mcg nasal spray	
Ferrlecit	Ferric Gluconate	12.5 mg injection	J2916- removed prior authorization for medical benefit as of 5/1/2024
INFeD	Iron Dextran	50 mg injection	J1750- removed prior authorization for medical benefit as of 5/1/2024
	Sumatriptan	All strengths of nasal spray	
Venofer	Iron Sucrose	1 mg injection	J1750- removed prior authorization for medical benefit as of 5/1/2024

IF APPLICABLE: THE FOLLOWING MEDICINES WILL BE NON-PREFERRED ON THE PDL EFFECTIVE APRIL 1, 2024.

Brand Name	Generic Name	Dose(s)	Notes
Airsupra	Albuterol/ Budesonide	90-80 mcg inhaler	Added age and quantity limits
	Azelastine/ Fluticasone	137-50 mcg nasal spray	
Xalkori	Crizotinib	250 mg capsules	
	Zolmitriptan	All strengths of nasal spray	

IF APPLICABLE: THE FOLLOWING MEDICINES HAVE A CHANGE IN STATUS

EFFECTIVE APRIL 1, 2024.

Brand Name	Generic Name	Dose(s)	Notes
	Adalimumab-aacf	40 mg/ 0.8 mL injection	Updated step therapy
	Adalimumab-adbm	All strengths of injection	Updated step therapy
	Adalimumab-fkjp	All strengths of injection	Updated step therapy
Adbry	Tralokinumab-ldrm	150 mg/ mL injection	
Advair HFA	Fluticasone/ Salmeterol	230-21 mcg HFA inhaler	Removed step therapy
Bimzelx	Bimekizumab	160 mg/ mL injection	Updated quantity limit
Cosentyx	Secukimumab	All strengths of injection	Updated step therapy
Dupixent	Dupilumab	All strengths of injection	Updated age limit
E.E.S Granules	Erythromycin ethylsuccinate	200 mg/ 5 mL oral granules	Updated step therapy
	Fluticasone/ Salmeterol	230-21 mcg HFA inhaler	Removed step therapy
Hadlima	Adalimumab-bwwd	All strengths of injection	Updated step therapy
Hemangeol	Propranolol	4.28 mg/ mL oral solution	Updated age limit and step therapy
Humira	Adalimumab	All strengths of injection	Updated step therapy
Idacio	Adalimumab-aacf	40 mg/ 0.8 mL injection	Updated step therapy
llaris	Canakinumab	150 mg/ mL injection	Updated prior authorization
Inpefa	Sotagliflozin	200mg and 400mg tablet	Updated step therapy
Katerzia	Amlodipine	1 mg/ 1 mL	Updated age limit and step therapy
Koselugo	Selumetinib	10 mg and 20 mg capsules	Updated quantity limit
Myalept	Metreleptin	11.3 mg vial for injection	Updated quantity limit

Norliqva	Amlodipine	1 mg/ 1 mL	Updated age limit and step therapy
Nymalize	Nimodipine	All strengths of oral solution	Updated age limit and step therapy
Omvoh	Mirikizumab	100 mg/ mL injection	Updated quantity limit
Qbrelis	Lisinopril	1 mg/ 1 mL oral solution	Updated age limit and step therapy
Rivfloza	Nedosiran	All strengths of injection	Updated quantity limit
Tysabri	Natalizumab	300 mg/ 15 mL injection	Updated step therapy
Velsipity	Estrasimod	2 mg tablet	Updated quantity limit
Xalkori	Crizotinib	All strengths of capsules and pellets	Updated quantity limit
Xeljanz	Tofacitinib	All strengths of tablet	Updated step therapy
Yuflyma	Adalimumab-aaty	All strengths of injection	Updated prior authorization
Zafemy	ethinyl estradiol/ norelgestromin	150-35/ 24H patch	Updated step therapy

What should you do?

First, talk to your prescriber. There may be other medicines on the CareSource PDL that you can take instead. There are a few ways you and your prescriber can find medicines:

- You can look on our website at **CareSource.com**. On the Members page, go to Tools & Resources and click on "Find My Prescriptions".
- Or, call our Member Services Department at 1-844-607-2829 (TTY: 1-800-743-3333 or 711).

We are here to help you. The Member Services Department is open Monday through Friday, 8 a.m. to 8 p.m. Eastern Time.

Sincerely,

CareSource RxInnovations

RR2022-IN-MMED-1895-V.7; First Use: 11/29/2022 OMPP Approved: 11/29/2022